Bioceltix S.A. Logo

Bioceltix S.A.

Develops stem cell-based medicinal products for veterinary use.

BCX | WAR

Overview

Corporate Details

ISIN(s):
PLBCLTX00019 (+1 more)
LEI:
259400QZD5JYK8SLZU51
Country:
Poland
Address:
Wrocław Bierutowska 57-59/BUD.III, 51-317 Wrocław

Description

Bioceltix S.A. is a biopharmaceutical company that develops stem cell-based medicinal products for veterinary use. The company focuses on creating therapies that utilize Mesenchymal Stem Cells (MSCs) as the active pharmaceutical ingredient. Its product pipeline is aimed at treating immunological and inflammatory conditions in companion animals, including dogs, cats, and horses. A key area of development includes treatments for conditions such as atopic dermatitis in dogs and degenerative joint disease.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-05-07 18:29
Informacja o liczbie akcji i głosów
Polish 74.3 KB
2024-05-07 18:29
Klauzula informacyjna o przetwarzaniu danych osobowych
Polish 174.2 KB
2024-05-07 18:29
Formularz głosowania przez pełnomocnika
Polish 160.9 KB
2024-05-07 18:29
Formularze pełnomocnictwa
Polish 115.1 KB
2024-05-07 18:29
Zestawienie zmian statutu
Polish 86.8 KB
2024-05-07 18:29
Opinia Zarządu
Polish 73.1 KB
2024-05-07 18:29
Projekty uchwał wraz z uzasadnieniem
Polish 148.9 KB
2024-05-07 18:29
Ogłoszenie o zwołaniu NWZ
Polish 145.2 KB
2024-05-07 18:29
Zwołanie NWZ na dzień 3 czerwca 2024 roku - Content (PL)
Polish 2.1 KB
2024-05-07 17:38
Przyjęcie planu budowy wielkoskalowej wytwórni komórek macierzystych i sposobu …
Polish 5.4 KB
2024-04-26 17:12
Podpisy do opinii biegłego rewidenta z badania Sprawozdania Finansowego Biocelt…
Polish 10.3 KB
2024-04-26 17:12
Opinia biegłego rewidenta z badania Sprawozdania Finansowego Bioceltix S.A. za …
Polish 2.9 MB
2024-04-26 17:12
Podpisy do Raportu okresowego rocznego Bioceltix S.A. za rok 2023
Polish 20.9 KB
2024-04-26 17:12
Raport okresowy roczny Bioceltix S.A. za rok 2023
Polish 17.3 MB
2024-04-26 17:12
Podpisy do Sprawozdania z Działalności Bioceltix S.A. za okres sprawozdawczy za…
Polish 20.9 KB

Automate Your Workflow. Get a real-time feed of all Bioceltix S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Bioceltix S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Bioceltix S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Coherus Oncology, Inc. Logo
Biopharmaceutical company developing and commercializing immuno-oncology therapies.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
A biopharmaceutical company developing abuse-deterrent pain management medications.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops plant-derived collagen for 3D bioprinting of tissues and organs.
United States of America
CLGN
COMPASS Pathways plc Logo
Develops psilocybin treatments for difficult-to-treat mental health conditions.
United States of America
CMPS
Compass Therapeutics, Inc. Logo
Clinical-stage biopharma developing antibody-based therapeutics for oncology.
United States of America
CMPX
Connect Biopharma Holdings Ltd Logo
A clinical-stage biopharma developing therapies for T cell-driven inflammatory diseases.
United States of America
CNTB
Context Therapeutics Inc. Logo
Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.
United States of America
CNTX
Contineum Therapeutics, Inc. Logo
Clinical-stage biopharma developing oral small molecule therapies for NI&I conditions.
United States of America
CTNM
Corbus Pharmaceuticals Holdings, Inc. Logo
Clinical-stage biopharma developing targeted therapies for oncology and obesity.
United States of America
CRBP
CORCEPT THERAPEUTICS INC Logo
Develops and commercializes cortisol-modulating medications for severe disorders.
United States of America
CORT

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.